Shots:

• EyePoint has dosed the first patient with Duravyu under the P-III (LUGANO) study for treating wet age-related macular degeneration (wet AMD). It is also being assessed under P-III (LUCIA) trial with first patient dosing planned in YE’24 and P-II (VERONA) study for DME with topline data in Q1’25
• The studies will assess the safety & efficacy of Duravyu vs aflibercept in wet AMD patients both naïve and experienced, each recruiting ~400 subjects worldwide. Patients will be administered an intravitreal injection, Q6M, beginning from 2nd month
• The 1EP of the studies include the change in BCVA at wks.52 and 56, while 2EPs are safety, reduced treatment burden, percentage of eyes without additional aflibercept & OCT-measured anatomical outcomes. Topline data is expected in 2026

Ref: EyePoint | Image: EyePoint

Related News:- EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com